XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segments
 3 Months Ended
Mar. 30, 2024
Segment Reporting [Abstract]  
Segments Segments
The Company’s two reportable segments are U.S. and International. U.S. segment revenues totaled $114,281 and $103,978 for the three months ended March 30, 2024 and April 1, 2023, respectively. International segment revenues totaled $15,176 and $15,081 for the three months ended March 30, 2024 and April 1, 2023, respectively. The Company’s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment Adjusted EBITDA is the segment profitability metric reported to the Company’s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.
The following table presents segment Adjusted EBITDA reconciled to loss before income taxes:
Three Months Ended
March 30, 2024April 1, 2023
Segment Adjusted EBITDA
U.S.$19,756 $14,712 
International2,867 2,239 
Interest expense, net(10,339)(9,694)
Depreciation and amortization(11,785)(16,473)
Acquisition and related costs(211)(1,175)
Shareholder litigation costs(1,168)— 
Restructuring and succession charges(53)(317)
Equity compensation(2,591)(1,846)
Financial restructuring costs(352)(5,330)
Impairments of assets— (78,615)
Other items(1,199)(3,665)
Loss before income taxes$(5,075)$(100,164)